BIOTRONIK’s Post

Global Medical Radiation Sterilization Equipment Market Scale: Size, Trends, and Forecasts 2024-2030 https://lnkd.in/gSzh8XUQ #marketanalysis #marketresearch #marketresearchreports #businessintelligence

MitraClip G4 is setting a new standard for TEER with the use of all Clip sizes in Asian patients to optimize therapy, resulting in significant reductions in mitral regurgitation after one year (MR <=1 in 99% of patients!!). Learn more by watching this video, which discusses the results of the Expand G4 trial conducted in Japan: https://lnkd.in/gfJ-3YVY #AbbottProud #ClipLeadingTEER

Ready to implement a new paradigm in personalized medicine and point-of-care diagnostics. With the world's first true mini LC-MS...

Follow the new BIOTRONIK Vascular Intervention page for latest updates!

ASCO daily highlights: Saturday 1st June Our precision medicine expert Ying Liu shares key highlights from day 2 at ASCO. Stay tuned to our LinkedIn page where we will be sharing our precision medicine expert daily highlights throughout the conference. Read our highlights here: https://lnkd.in/ei4-nrdj Schedule a meeting with one of our solution experts at ASCO using the link below to learn more about how Diaceutics are uniquely positioned to help you achieve commercialization success for your precision medicine: https://lnkd.in/gnZMEG3p #ASCO2024 #ASCO24 #PrecisionMedicine

For those of you who prefer shorter videos, here's the 5 Things to Know for the week - Thing 3: DKI Releases Report on Shockwave Medical ($SWAV) https://lnkd.in/e5KVu8kR

A few thoughts from the top of the morning here: In just a little over a year, J&J has gone from Mr./Mrs. Irrelevant to perhaps the compelling suite of products in the Cardiac/Vascular market. Pretty Impressive. Hopefully J&J continues to leave Abiomed alone, and does so with Shockwave...a la what they did w/ Biosense Webster. If they go in and J&J'ify everything, innovation will stop faster than a production line with a wrench tossed in it's gears. If Shockwave's acquisition of Neovasc, a coronary sinus reducer for refractive angina ever bears any fruit...$13.1 B will seem like a song for this acquisition. J&J means business this time. They have often said they wanted to become a major player again in Cardiac/Vascular, dating back to their once imminent acquisition of Guidant. But actions speak louder than words. They are likely far from done. Percutaneous valve technologies are the glaring omission from their shiny new product portfolio. An acquisition of Edwards would be the lynch pin here, striking fear in the hearts and minds of Hospital Purchasing execs across America. Or maybe they start small, acquiring some of the earlier stage companies that are showing positive results from first in man trials across the various markets: Aortic, Mitral & Tricuspid? Maybe they look at the one "non strategic owned" commercial stage perc valve company on the market as an entry point? Time will tell, fun to speculate...

The latest Board and Commission Medical Digest is packed with invaluable insights, including: 📍An in-depth look at the Physician Workforce Act of 2023 📍Critical concerns surrounding Semaglutide/GLP-1 Receptor Agonists 📍Insights into APP Specialty Skills Protocols https://bit.ly/3tO4RMv 📚 #MedicalNews #HealthcareUpdates #StayInformed"

Learn about The Rayocomp PS 100 polar 4.0 Med high end medical device for the Successful Treatment of Chronic Pain: A new clinical prospective, double-blind, randomised, placebo-controlled study proves the efficacy and safety of Bioresonance According to Paul Schmidt #ipmcongress - via #Whova Event Platform

For those of you who prefer shorter videos, here's the 5 Things to Know for the week - Thing 3: DKI Releases Report on Shockwave Medical ($SWAV) https://lnkd.in/eqaz2h3y